Spero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Spero Therapeutics received a reaffirmed "sell (D-)" rating from Weiss Ratings, amidst mixed ratings from other analysts, including a recent upgrade to "strong-buy" by Zacks Research.
• Shares of Spero Therapeutics traded up by 5.6%, opening at $2.28, with a 1-year price range of $0.51 to $3.22.
• Recently, institutional investors increased their holdings in Spero Therapeutics, with Anson Funds Management raising its stake by 98.9% in the first quarter.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other equities analysts have also recently commented on SPRO. Zacks Research upgraded shares of Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Monday. Wall Street Zen upgraded shares of Spero Therapeutics to a "hold" rating in a research note on Saturday, June 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Spero Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Spero Therapeutics Trading Up 5.6%

Shares of Spero Therapeutics stock opened at $2.28 on Wednesday. The firm has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $1.78. Spero Therapeutics has a 1-year low of $0.51 and a 1-year high of $3.22. The stock has a market capitalization of $128.32 million, a price-to-earnings ratio of -2.33 and a beta of 1.47.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.35. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. The business had revenue of $14.19 million during the quarter, compared to analysts' expectations of $11.00 million. As a group, research analysts predict that Spero Therapeutics will post -1.2 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Anson Funds Management LP raised its stake in shares of Spero Therapeutics by 98.9% in the first quarter. Anson Funds Management LP now owns 7,638,818 shares of the company's stock valued at $5,500,000 after acquiring an additional 3,798,932 shares during the last quarter. Mackenzie Financial Corp boosted its stake in Spero Therapeutics by 11.4% in the first quarter. Mackenzie Financial Corp now owns 209,031 shares of the company's stock worth $151,000 after purchasing an additional 21,472 shares in the last quarter. Capital Asset Advisory Services LLC acquired a new position in Spero Therapeutics in the second quarter worth $94,000. XTX Topco Ltd acquired a new position in Spero Therapeutics in the second quarter worth $100,000. Finally, Invesco Ltd. acquired a new position in Spero Therapeutics in the second quarter worth $43,000. Institutional investors own 25.60% of the company's stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.